CERo Therapeutics Hldgs Bolsa (NASDAQ: CERO)

Últimas noticias sobre CERo Therapeutics Hldgs (NASDAQ:CERO) Bolsa

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

TJX Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TJX#NYSE">TJX</a>) short percent of float has risen 21.7% since its last report. The company recently reported that it has 14.55 million shares sold short, which is 1.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.49 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TJX Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734549321_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TJX Companies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TJX Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TJX Companies's peer group average for short interest as a percentage of float is 14.98%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into TJX Companies's Recent Short Interest

Exelixis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NYSE">EXEL</a>) short percent of float has risen 5.91% since its last report. The company recently reported that it has 8.36 million shares sold short, which is 3.94% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Exelixis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734549316_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Exelixis has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Exelixis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Exelixis's peer group average for short interest as a percentage of float is 4.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

EXEL

Peering Into Exelixis's Recent Short Interest

East West Bancorp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NYSE">EWBC</a>) short percent of float has fallen 6.0% since its last report. The company recently reported that it has 4.03 million shares sold short, which is 3.29% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>East West Bancorp Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734549311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for East West Bancorp has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing East West Bancorp's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, East West Bancorp's peer group average for short interest as a percentage of float is 3.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

EWBC

Looking Into East West Bancorp's Recent Short Interest

MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is doubling down on <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42560698/microstrategys-aggressive-bitcoin-strategy-raises-eyebrows-in-crypto-community">its strategy to maximize shareholder value</a> through what Saylor calls &#8220;intelligent leverage.&#8221;
The software-turned-Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) proxy firm has become a major player in the cryptocurrency market, attracting significant investor attention due to its bold approach to Bitcoin accumulation.
"We have $7.2 billion in convertibles, with $4 billion effectively equity through the strike and call price. They are trading with a delta of nearly 100%, resembling equity," Saylor explained during a Bloomberg Television <a href="https://www.bloomberg.com/news/articles/2024-12-18/microstrategy-s-saylor-wants-to-add-more-intelligent-leverage?cmpid%3D=socialflow-twitter-tv&amp;utm_medium=social&amp;utm_campaign=socialflow-organic&amp;utm_content=tv&amp;utm_source=twitter&amp;embedded-checkout=true">interview</a> on Wednesday. "We aim to develop more intelligent leverage for the benefit of our common stock shareholders."
MicroStrategy has been at the forefront of an unconventional capital-raising campaign to acquire Bitcoin, announcing multibillion-dollar purchases of the cryptocurrency every Monday for the past six weeks. 
This aggressive strategy has catapulted the company's stock price by nearly 500% this year, significantly outpacing Bitcoin's 150% gains over the same period.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42556544/doge-meme-ip-owner-acquires-new-rights-as-fartcoin-continues-to-surge">Doge Meme IP Owner Acquires New Rights As Fartcoin Continues To Surge</a>
The company's market capitalization has surged to over $90 billion, paving the way for its <a href="https://www.benzinga.com/markets/equities/24/12/42503221/microstrategy-shares-surge-nearly-7-amid-nasdaq-100-inclusion-and-bitcoins-new-record-high">inclusion in the Nasdaq 100 Index</a> by the end of trading Friday.
This inclusion is expected to trigger approximately $2 billion in purchases by funds that track the index, according to Bloomberg Intelligence.
MicroStrategy's approach has also drawn interest from hedge funds engaging in convertible arbitrage strategies. 
These involve buying the company's fixed-income securities while shorting its shares, capitalizing on the stock's volatility. 
This demand has enabled MicroStrategy to issue <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42509614/microstrategy-expands-bitcoin-holdings-by-15350-btc-worth-15-billion-after-joining-nasdaq-100">$6.2 billion worth of convertible bonds</a> this year alone.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42556138/bitcoin-bulls-should-stay-the-course-ahead-of-federal-reserve-meeting-says-qcp-capital">Bitcoin Bulls Should &#8216;Stay The Course&#8217; Ahead Of Federal Reserve Meeting, Says QCP Capital</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy Chairman Michael Saylor Eyes' Intelligent Leverage' With Bitcoin Purchases

The Federal Reserve closed out the year with a widely anticipated 25 basis-point interest rate cut Wednesday, lowering the federal funds rate to a<a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42556652/20-etfs-primed-for-unusually-big-swings-on-fed-meeting-days"> range of 4.25%-4.5%. </a>
This marks the lowest level since January 2023 and is the third consecutive reduction in borrowing costs, following a 50-basis-point cut in September and a 25 basis-point move in November.
The decision to lower interest rates was not unanimous, as Cleveland Fed President Beth M. Hammack voted to maintain the target range unchanged at 4.5%-4.75%.
The Fed's statement showed a meaningful language change, with the addition of the words &#8220;extent&#8221; and &#8220;timing&#8221; in reference to future policy adjustments. This shift signals a more cautious approach to further rate cuts in 2025.
&#8220;In considering the extent and timing of additional adjustments, to the target range for the federal funds rate, the Committee will carefully assess incoming data, the evolving outlook, and the balance of risks,&#8221; the December Federal Open Market Committee statement said. 
<h3 class="wp-block-heading">Economic Projections Signal Fewer Rate Cuts, Higher Inflation</h3>
The Fed&#8217;s December dot plot, which illustrates each policymaker&#8217;s projected path for interest rates, indicates a median expectation for the federal funds rate to decrease to a midpoint of 3.9% by the end of 2025.
This projection suggests the potential of only two additional 0.25% rate cuts during next year, a meaningful revision from the full percentage point of cuts expected in September.
For 2026, the Fed projects the fed funds rate to fall to a midpoint of 3.4%, up from 2.9% in September.
The Fed materially raised its inflation expectations for 2025, projecting headline Personal Consumption Expenditure inflation at 2.5% compared to 2.1% in September. Core PCE inflation, which excludes volatile food and energy prices, is now forecast to reach 2.5% in 2025, up from the prior estimate of 2.2%.
The Fed reaffirmed that economic activity remains &#8220;solid&#8221; and said that, despite some easing in labor market conditions, the unemployment rate continues to be low.
Economic growth for 2025 was upwardly revised by 0.1 percentage points from September. 
Leading into the December Fed meeting, money markets priced in an 80% probability of a rate pause in January, followed by a 60% likelihood of a rate cut in March.
Overall, CME FedWatch data reflected a 70% probability of at least three rate cuts by the end of 2025.
In contrast, the CFTC-regulated betting platform Kalshi showed a more aggressive outlook, with a 98% chance of four rate reductions next year.
<h3 class="wp-block-heading">Fed&#8217;s December Summary of Economic Projections</h3>
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Variable</th>
<th>2024</th>
<th>2025</th>
<th>2026</th>
<th>2027</th>
<th>Longer Run</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in real GDP</td>
<td>2.4</td>
<td>2.1</td>
<td>2.0</td>
<td>1.9</td>
<td>1.8</td>
</tr>
<tr>
<td>Sept. projection </td>
<td>2.0 </td>
<td>2.0 </td>
<td>2.0 </td>
<td>2.0 </td>
<td>1.8 </td>
</tr>
<tr>
<td>Unemployment rate</td>
<td>4.2</td>
<td>4.3</td>
<td>4.3</td>
<td>4.3</td>
<td>4.2</td>
</tr>
<tr>
<td>Sept. projection</td>
<td>4.4</td>
<td>4.4</td>
<td>4.3</td>
<td>4.2</td>
<td>4.2</td>
</tr>
<tr>
<td>PCE inflation </td>
<td>2.4</td>
<td>2.5 </td>
<td>2.1</td>
<td>2.0 </td>
<td>2.0 </td>
</tr>
<tr>
<td>Sept. projection</td>
<td>2.3</td>
<td>2.1</td>
<td>2.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Core PCE inflation </td>
<td>2.8 </td>
<td>2.5</td>
<td>2.1</td>
<td>2.0 </td>
<td></td>
</tr>
<tr>
<td>Sept. projection</td>
<td>2.6</td>
<td>2.2</td>
<td>2.0</td>
<td>2.0</td>
<td></td>
</tr>
<tr>
<td>Federal funds rate </td>
<td>4.4</td>
<td>3.9</td>
<td>3.4</td>
<td>3.1 </td>
<td>3.0</td>
</tr>
<tr>
<td>Sept. projection</td>
<td>4.4</td>
<td>3.4</td>
<td>2.9</td>
<td>2.9</td>
<td>2.9</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Federal Reserve </figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42539116/fed-meetings-made-stock-traders-richer-in-2024-could-wednesday-bring-last-big-rally">Fed Meetings Made Stock Traders Richer In 2024: Could Wednesday Bring Last Big Rally?</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Econ #s

Economics

Federal Reserve

Fed Slashes Interest Rates By 0.25% As Predicted: December Dot Plot Flags Only 2 Potential Cuts In 2025

WIIM

AMST

Amesite shares are trading higher after the company disclosed its healthcare app Nursemagic won contracts with hundreds of high-growth companies across the country.

BYON

Beyond shares are trading lower after Argus Research downgraded the stock from Hold to Sell.

JPMorgan analyst Cory Carpenter downgraded Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Overweight to Neutral and lowered the <a href="https://www.benzinga.com/quote/MTCH/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $40 to $33</a>.
Match is the leading online dating platform with an estimated ~50% share of global dating users across its portfolio of brands. Tinder is the largest and most profitable dating app globally and Hinge is the fastest-growing scaled dating brand.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/12/42529040/on-semiconductor-and-denso-team-up-to-boost-self-driving-tech" rel="noreferrer noopener">ON Semiconductor and Denso Team Up to Boost Self-Driving Tech</a>
The rerating reflects Carpenter&#8217;s expectation for muted growth in the online dating industry in 2025 and limited visibility in the timing and magnitude of the Tinder turnaround. The analyst noted the downside is limited due to undemanding valuation, low investor expectations, dividends and share buybacks, and activism.
Heading into 2024, Carpenter expected Tinder payers to stabilize as the focus shifted from price optimizations to product and marketing.
However, the Tinder turnaround has proven more difficult than expected, and much work remains to return Tinder to sustainable growth.&nbsp;&nbsp;
The analyst noted Tinder user and revenue trends need to improve for Match shares to rerate higher, which appears increasingly unlikely in 2025.
Indeed, Tinder revenue and users will likely worsen before improving, with a return to growth not forecasted until 2027.&nbsp;&nbsp;
Carpenter updated his model following the investor day last week, with his Tinder direct revenue estimate reduced by 10% in 2026. This reflects a revenue decline of 6% in 2025, flat in 2026, and up 2% in 2027. The analyst still noted Tinder stability is possible over time through AI-driven product innovation, but it remains early, and execution is critical.
The price target is based on nine times Carpenter&#8217;s 2025E AOI of $1.3 billion, which is a discount to Grindr Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>), which trades at 18 times, but a premium to Bumble Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMBL#NASDAQ">BMBL</a>), which trades at six times.
MTCH Price Action: Match Group stock is up 0.57% at $31.76 at publication Wednesday
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42520765/super-micro-drops-below-50-day-average-faces-nasdaq-100-removal-just-months-after-entry" target="_blank" rel="noreferrer noopener">Super Micro Drops Below 50-Day Average, Faces Nasdaq 100 Removal Just Months After Entry</a></li>
</ul>
Photo: Mojahid Mottakin via Shutterstock

Downgrades

Price Target

Analyst Ratings

Movers

BMBL

GRND

MTCH

Match Group Analyst Flags Tinder Woes, Industry Challenges For Stock Downgrade

Macro Economic Events

Macro Notification

General

Fed Interest Rate Decision Lowered 25 Basis Points To 4.50% Vs 4.50% Est.; 4.75% Prior

RIME

Algorhythm Holdings shares are trading higher after its subsidiary SemiCab won a new pilot program with the 6th largest global consumer package goods company.

Fed Policymakers See 4.3% Unemployment Rate At End Of 2025 Versus 4.4% In September Projections; End-2025 PCE Inflation At 2.5% Versus 2.1% In September; Core Seen At 2.5% Versus 2.2%; 2.1% GDP Growth In 2025 Versus 2.0% In September, See Longer-run Growth At 1.8%, Unchanged From September

Fed Projections Imply 50 Basis Points Of Rate Cuts In 2025, Another 50 Bps In 2026; Fed Policy Rate Reaching 3.1% In 2027; Show Longer-run Policy Rate At 3.0% Vs 2.9% In September Projections; One Of 19 Officials See No Cuts In 2025, 3 See One Cut, 10 See 2 Cuts, 3 See 3 Cuts, One Sees 4 Cuts, One Sees 5 Cuts; Stronger Growth And Stronger Inflation In 2025

Fed Officials' Median View Of Fed Funds Rate At End-2024 4.4% (Prev 4.4%); Fed Officials' Median View Of Fed Funds Rate At End-2025 3.9% (Prev 3.4%); Fed Officials' Median View Of Fed Funds Rate At End-2026 3.4% (Prev +2.9%); Fed Officials' Median View Of Fed Funds Rate At End-2027 3.1% (Prev +2.9%); Fed Officials' Median View Of Fed Funds Rate In Longer Run 3.0% (Prev 2.9%)

Fed Says In Considering 'extent And Timing' Of Additional Rate Adjustments Fed Will Assess Incoming Data, Evolving Outlook, Balance Of Risks; Lowers Reverse Repo Rate By 30 Basis Points To 4.25% Versus 25 Bps Cut To Fed Funds Rate; Fed Vote In Favor Of Rate Cut Was 11-1; Cleveland Fed President Hammack Dissented, Preferring To Leave Policy Rate Unchanged

Small Cap

Federal Reserve Cuts Key Overnight Interest Rate 25 Basis Points To 4.25-4.50% Range; New Projections Show 50 Bps Of Cuts In 2025; Fed Policy Statement Little Changed From November Meeting Statement; Descriptions Of Economy Growing At Solid Pace Are Identical

Analysts' ratings for Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) over the last quarter vary from bullish to bearish, as provided by 23 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $92.87, with a high estimate of $135.00 and a low estimate of $70.00. This current average reflects an increase of 26.05% from the previous average price target of $73.68. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548458_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Twilio's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$110.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$115.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Buy</td>
<td>$135.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$77.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Taylor McGinnis</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$88.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Michael Latimore</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$86.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>J. Derrick Wood</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$85.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$85.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$77.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Twilio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Twilio compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Twilio's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Twilio's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TWLO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Twilio analyst ratings.</a>
<h2>About Twilio</h2>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
<h3>Financial Insights: Twilio</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Twilio showcased positive performance, achieving a revenue growth rate of 9.67% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.86%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.11%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Twilio's ROA excels beyond industry benchmarks, reaching -0.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Twilio's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TWLO

Demystifying Twilio: Insights From 23 Analyst Reviews

Ratings for PTC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for PTC, presenting an average target of $217.29, a high estimate of $230.00, and a low estimate of $195.00. Witnessing a positive shift, the current average has risen by 7.04% from the previous average price target of $203.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734548446_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive PTC. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$228.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PTC. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PTC compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for PTC's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of PTC's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PTC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PTC analyst ratings.</a>
<h2>About PTC</h2>
PTC offers high-end computer-assisted design (Creo) and product lifecycle management (Windchill) software as well as Internet of Things and AR industrial solutions. Founded in 1985, PTC has 28,000 customers, with revenue stemming mostly from North America (45%) and Europe (40%).
<h3>PTC's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, PTC showcased positive performance, achieving a revenue growth rate of 14.62% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: PTC's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 20.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): PTC's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 4.06%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): PTC's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.02%, the company may face hurdles in achieving optimal financial performance.
Debt Management: PTC's debt-to-equity ratio surpasses industry norms, standing at 0.6. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying PTC: Insights From 7 Analyst Reviews

Throughout the last three months, 11 analysts have evaluated TechnipFMC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTI#NYSE">FTI</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $36.0, a high estimate of $42.00, and a low estimate of $31.00. Observing a 5.11% increase, the current average has risen from the previous average price target of $34.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548435_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of TechnipFMC by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Ati Modak</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Buy</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Victoria McCulloch</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Abhishek Kumar</td>
<td>HSBC</td>
<td>Announces</td>
<td>Buy</td>
<td>$32.00</td>
<td>-</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$37.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Marc Bianchi</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$37.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Chase Mulvehill</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Phillip Jungwirth</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to TechnipFMC. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of TechnipFMC compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for TechnipFMC's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of TechnipFMC's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FTI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on TechnipFMC analyst ratings.</a>
<h2>Discovering TechnipFMC: A Closer Look</h2>
TechnipFMC is the largest pure-play offshore oilfield service provider, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea engineering and construction services. The company also provides various surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of predecessor companies Technip and FMC Technologies.
<h3>Financial Insights: TechnipFMC</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Positive Revenue Trend: Examining TechnipFMC's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.17% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.
Net Margin: TechnipFMC's net margin is impressive, surpassing industry averages. With a net margin of 11.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): TechnipFMC's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.81% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): TechnipFMC's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.9% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: TechnipFMC's debt-to-equity ratio is below the industry average at 0.6, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For TechnipFMC

In the preceding three months, 4 analysts have released ratings for Huntsman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUN#NYSE">HUN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $22.75, a high estimate of $25.00, and a low estimate of $19.00. A 2.15% drop is evident in the current average compared to the previous average price target of $23.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1734548427_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of Huntsman's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Huntsman. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Huntsman compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Huntsman's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Huntsman's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Huntsman analyst ratings.</a>
<h2>Unveiling the Story Behind Huntsman</h2>
Huntsman Corp is a us-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives most of its revenue from the Polyurethanes segment which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States &amp; Canada, Europe, Asia-Pacific, and the Rest of the world.
<h3>Key Indicators: Huntsman's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Huntsman showcased positive performance, achieving a revenue growth rate of 2.26% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Huntsman's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -2.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Huntsman's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.06%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Huntsman's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.45%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.73.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Huntsman Stock

11 analysts have expressed a variety of opinions on Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $112.09, a high estimate of $125.00, and a low estimate of $104.00. This upward trend is apparent, with the current average reflecting a 1.73% increase from the previous average price target of $110.18.
<img src="https://www.benzinga.com/files/images/story/2024/1734548418_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Eastman Chemical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$104.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$117.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eastman Chemical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Eastman Chemical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Eastman Chemical's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>Get to Know Eastman Chemical Better</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Understanding the Numbers: Eastman Chemical's Finances</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Eastman Chemical showcased positive performance, achieving a revenue growth rate of 8.69% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Eastman Chemical's net margin is impressive, surpassing industry averages. With a net margin of 7.31%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eastman Chemical's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.2% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Eastman Chemical Stands With Analysts

CERo Therapeutics files to sell 713.6M shares of common stock for holders

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound CER-1236.

CERo Therapeutics' (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data

FOXO Technologies, CERo Therapeutics Holdings, and Mullen Automotive are the 3&nbsp;Penny Stocks&nbsp;to watch on November 14, 2024, based on&nbsp;...

3 Penny Stocks to Watch Now, 11/24/24

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug Application for Ph...

Cero Therapeutics receives FDA clearance of IND application for CER-1236

CERo Therapeutics Holdings, Simpple Ltd., and Arena Group Holdings are the 3&nbsp;Penny Stocks&nbsp;to watch on November 19, 2024, based on&nbsp;Ti...

3 Penny Stocks to Watch Now, 11/19/24

06:23 EST Cero Therapeutics (CERO) files to sell 210M shares of common stock for holders Published first on TheFly – the ultimate source for real-t...

Cero Therapeutics files to sell 210M shares of common stock for holders

CERo Therapeutics (CERO) announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Publi...

Cero Therapeutics names Chris Ehrlich as CEO

Cero Therapeutics (CERO) announced its board of directors has appointed Chris Ehrlich as CEO. Previously he held the position of interim CEO. In ad...

Cero Therapeutics appoints Chris Ehrlich as CEO

CERo Therapeutics Holdings ( ($CERO) ) just unveiled an announcement. CERo Therapeutics, an innovative immunotherapy company, has appointed Chris E...

CERo Therapeutics Appoints New CEO to Lead Innovations

CERo Therapeutics appoints Chris Ehrlich CEO

AREN

FOXO

LPAA

MULN

SPPL

Press Releases

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

Health Care

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Comments

CERo Therapeutics Hldgs

Noticias

Últimas noticias sobre CERo Therapeutics Hldgs (NASDAQ:CERO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL